Ad hoc announcement pursuant to § 15 WpHG

Carl Zeiss Meditec in advanced negotiations with Abbott Medical Optics Inc. about US commercial collaboration agreement in the field of cataract surgery


JENA/Germany, 16/10/2014.

Carl Zeiss Meditec AG (ISIN: DE0005313704) is in advanced negotiations about a US commercial collaboration agreement with Abbott Medical Optics Inc. (AMO), Santa Ana, USA in the field of cataract surgery. Closing of the collaboration agreement is expected shortly.

The aim of the collaboration is to establish a new distribution channel for ZEISS devices for cataract surgery in addition to the existing ZEISS sales channel.

The intended agreement shall be non-exclusive and limited to the US market.

Press contact:
Jann Gerrit Ohlendorf, Group Communications, Carl Zeiss Meditec AG
Phone: +49 (0)3641 220-331, Email: press .meditec @zeiss .com


For investors:
Sebastian Frericks, Investor Relations, Carl Zeiss Meditec AG
Phone: +49 (0)3641 220-116, Email: investors .meditec @zeiss .com

Brief profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases - including implants and consumable materials. The company creates innovative visualisation solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In financial year 2012/2013 (ended 30 September) the Group's more than 2,500 employees generated revenue of almost € 906 million.

The head office of Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Research and Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
Carl Zeiss offers innovative solutions for the future-oriented markets of Medical and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products. Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Foundation.


For more information visit:
www.meditec.zeiss.com/press
www.meditec.zeiss.com